Research output per year
Research output per year
Personal profile
Personal profile
After completing his postdoctoral training, Dr. Brown joined the faculty at the Baylor College of Medicine as a Clinical Instructor in the Department of Ophthalmology. He received his faculty appointment at the Weill Medical College in 2006.
Research interests
Dr. Brown’s research centers on clinical investigations to evaluate treatments for diabetic retinopathy, neovascular age-related macular degeneration, central retinal vein occlusion, and retinal detachment. Dr. Brown was a key investigator on the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-related Macular Degeneration (ANCHOR) Study and the Minimally classic/occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular AMD (MARINA) Study which both demonstrated a statistically significant benefit of Lucentis (ranibizumab) over Visudyne (verteporfin photodynamic therapy [PDT]) in predominantly classic choroidal neovascularization (CNV). Dr. Brown is also a member of the Diabetic Retinopathy Clinical Research Network.
Education/Academic qualification
Vitreoretinal Diseases & Surgery , Clinical Fellowship
Jul 1 1993 → Jun 30 1995
Award Date: Jun 30 1995
MD, Baylor College of Medicine
May 1 1990 → Jun 1 1994
Award Date: Jun 1 1994
Ophthalmology, Residency, University of Iowa Hospitals and Clinics
Jul 1 1990 → Jun 30 1993
Award Date: Jun 30 1993
Internship, Baylor College of Medicine
Jul 1 1988 → Jun 30 1989
Award Date: Jun 30 1989
Research Area Keywords
- Clinical Care
- Clinical Translation & Trials
Free-text keywords
- Diabetic retinopathy
- Neovascular age-related macular degeneration
- Central retinal vein occlusion
- Retinal detachment
Fingerprint
Dive into the research topics where David M. Brown is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Baseline retinal vascular bed area on ultra-wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to ranibizumab therapy: two-year analysis of the DAVE Study
Fan, W., Uji, A., Wykoff, C. C., Brown, D. M., van Hemert, J., Falavarjani, K. G., Wang, K., Sadda, S. V. R. & Ip, M., Mar 2023, In: Eye (Basingstoke). 37, 4, p. 678-683 6 p.Research output: Contribution to journal › Article › peer-review
-
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
TENAYA and LUCERNE Investigators, Feb 19 2022, In: The Lancet. 399, 10326, p. 729-740 12 p.Research output: Contribution to journal › Article › peer-review
47 Scopus citations -
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
YOSEMITE and RHINE Investigators, Feb 19 2022, In: The Lancet. 399, 10326, p. 741-755 15 p.Research output: Contribution to journal › Article › peer-review
50 Scopus citations -
Exploring the angiographic-biologic phenotype in the IMAGINE study: Quantitative UWFA and cytokine expression
Abraham, J. R., Wykoff, C. C., Arepalli, S., Lunasco, L., Yu, H. J., Martin, A., Mugnaini, C., Hu, M., Reese, J., Srivastava, S. K., Brown, D. M. & Ehlers, J. P., Oct 1 2022, In: British Journal of Ophthalmology. 106, 10, p. 1444-1449 6 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT in DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial
Brown, D. M., Boyer, D. S., Csaky, K., Vitti, R., Perlee, L., Chu, K. W., Asmus, F., Leal, S., Zeitz, O., Cheng, Y., Schmelter, T. & Heier, J. S., Jun 1 2022, In: Retina. 42, 6, p. 1111-1120 10 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations